CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Summary

This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. Subjects will be enrolled into one of two treatment cohorts: subjects who will receive CART123 alone (Cohort A) or subjects who will receive CART123 in combination with ruxolitinib (Cohort B).

Eligibility

Inclusion Criteria:

* 1\. Age at time of consent: Cohort A: 0-29 years. Cohort B: 1-29 years (Note: the first subject at each dose level of Cohort B must be ≥12 years old)
* 2\. Subjects with AML in second or greater relapse, post-transplant relapse, or with chemotherapy-refractory disease. Specifically:

  1. Second or greater relapse defined as flow cytometric confirmation of myeloid leukemia of at least 0.1% after second documented complete remission; OR
  2. Any detectable disease post-allogeneic transplant with flow cytometric confirmation of myeloid leukemia of at least 0.1%; OR
  3. Refractory disease, defined as: Persistent bone marrow involvement with \>5% blasts after two courses of induction chemotherapy for patients at initial presentation, \>5% bone marrow blasts after one course of induction chemotherapy for patients who have relapsed after previously achieving a CR, and \>5% bone marrow blasts after one course of AML-directed chemotherapy for those with myeloid lineage switch.
* 3\. Subjects must have an identified stem cell donor with the ability to proceed rapidly to transplant following CART123 treatment if indicated.
* 4\. Adequate organ function defined as:

  1. Serum creatinine based on age/gender.
  2. Adequate liver function: ALT ≤ 500 U/L, Bilirubin ≤3x the upper limit of normal, and ALT and/or bilirubin results that exceed this range are acceptable if, in the opinion of the physician-investigator (or as confirmed by liver biopsy), the abnormalities are directly related to AML infiltration of the liver.
  3. Must have a minimum level of pulmonary reserve defined as ≤Grade 1 dyspnea and \<Grade 3 hypoxia; DLCO ≥ 40% (corrected for anemia if necessary) if PFTs are clinically appropriate as determined by the treating investigator.
  4. Left Ventricular Shortening Fraction (LVSF) ≥ 28% or Ejection Fraction (LVEF) ≥ 45% confirmed by echocardiogram or another scan.
* 5\. Adequate performance status defined as Lansky or Karnofsky performance score ≥ 50.
* 6\. Subjects of reproductive potential must agree to use acceptable birth control methods.

Exclusion Criteria:

* 1\. Active hepatitis B or active hepatitis C
* 2\. HIV infection
* 3\. Active acute or chronic GVHD requiring systemic therapy
* 4\. Concurrent use of systemic steroids or immunosuppression at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy or immunosuppression during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well.
* 5\. CNS disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity.
* 6\. Pregnant or nursing (lactating) subjects.
* 7\. Uncontrolled active infection

Conditions2

Interventions2

Locations1 site

Find trials near these locations

Related trials

• Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies — Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Browse More Trials